 |
 |
Krakow, Poland, September 24, 2015 / B3C newswire / -- Selvita, the largest drug discovery company in Central and Eastern Europe, is expanding its activity in the field of bioinformatics and personalized medicine. The new subsidiary, Ardigen, will take over Selvita current bioinformatics division activity with an aim of its further development and expansion.
Ardigen combines the competencies of information technology teams with the creative approach of biologists and chemists which contributed to the success of Selvita. The company will focus on three strategic business units. The scope of bioinformatics services developed until now by Selvita, will be expanded by the Big Data integration and analysis services, as well as custom application development. New business units will be developed based on services related to biological and clinical data analysis in the area of genomics, transcriptomics, proteomics, metabolomics and immunomics, as well as products and services within the field of personalized medicine.
The co-founder, and Chief Executive Officer of Ardigen is Janusz Homa, an experienced information technology manager, the co-founder and former Chief Executive Officer of Software Mind, a Polish software house delivering innovative solutions and IT services for international customers. Mr. Homa is also the former Vice President of Comarch Telecom, as well as co-founder of BillBird, the operator of the first in Poland alternative payment network allowing to pay the bills at the point of sale.
Sebastian Kwasny, the Director of Bioinformatics and Member of the Management Board of Selvita, has taken the position of Vice President of Operations at Ardigen.
“Starting Ardigen is our response to the vast amount of information on the mechanisms, progression and treatment outcomes of various life-threatening disorders and related new therapies, a challenge which doctors currently face without adequate and affordable solutions. We observe growing importance of data processing technologies in design and development of new drugs, as well as in diagnostics and treatment. We want to serve these unmet patient needs and I truly believe we can help them thanks to the team of world-class specialists who create Ardigen.” – commented Pawel Przewiezlikowski, Selvita Chief Executive Officer and President of the Supervisory Board at Ardigen.
“Advanced IT technologies are essential to achieve the promise of personalized medicine. This is what allows us to reach the knowledge contained in the petabytes of information gathered in various research institutes, clinics and by contributed patients. The marriage of the scientific potential and drug discovery experience of Selvita, with the possibilities offered by the modern IT technologies in the hands of our top-class informaticians and software developers, opens up a huge, completely new area of technology solutions supporting the most difficult battle any human being will ever face, the battle for health. – commented Janusz Homa, Ardigen Chief Executive Officer. “In the coming years, bioinformatics will play an even more crucial role in the life science and healthcare sectors. This is a market of an enormous potential which is only starting to develop. For Ardigen, it’s a perfect moment to start the race for the position of a global leader.”
Taking over the existing activity of Selvita bioinformatics department, Ardigen is starting off with a team of twenty employees and several important collaborations with some of the most significant industry players such as Abbott Informatics, Microsoft, Oracle, IBM and Qiagen.
The company plans to increase its headcount significantly in the near future and initiate new product and service development activities based on creative ideas of its founders.
About Selvita
Selvita is a drug discovery company with offices in Cambridge, Massachusetts, San Bruno in California, Cambridge, United Kingdom and Krakow, Poland. Selvita is engaged in the discovery and development of breakthrough medicines to treat oncology disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 275 people, including 86 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2016. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the Warsaw Stock Exchange in Poland and has a market capitalization of $ 70MM (SLV).
About Ardigen
Ardigen is a Polish bioinformatics company, part of the Selvita Group. The company is active in the field of laboratory information management systems, biological and clinical data analysis, Big Data integration, as well as custom application development. Through its know-how, experience and products, Ardigen supports the life science and healthcare industries in executing the idea of personalized medicine. Ardigen employs world-class specialists in the field of bioinformatics, biotechnology, mathematics, statistics and computer science. Company headquarters are located in Krakow, Poland.
Contact
Natalia Baranowska
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 784 069 418